Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials

JS Heier; D Pieramici; U Chakravarthy; SS Patel; S Gupta; A Lotery; EM Lad; D Silverman; EC Henry; M Anderesi; EA Tschosik; S Gray; D Ferrara; R Guymer

Journal article

Visual Function Decline Resulting from Geographic Atrophy: Results from the Chroma and Spectri Phase 3 Trials

JS Heier, D Pieramici, U Chakravarthy, SS Patel, S Gupta, A Lotery, EM Lad, D Silverman, EC Henry, M Anderesi, EA Tschosik, S Gray, D Ferrara, R Guymer

Ophthalmology Retina | ELSEVIER INC | Published : 2020

DOI: 10.1016/j.oret.2020.01.019

Open access

Abstract

Purpose: To assess visual function outcomes to 48 weeks in patients with bilateral geographic atrophy (GA) secondary to age-related macular degeneration included in 2 interventional clinical trials: relationship to baseline lesion size, outcomes by baseline lesion characteristic subgroups, and correlation of visual function outcomes with GA area. Design: The Chroma and Spectri studies (ClinicalTrials.gov identifiers, NCT02247479 and NCT02247531, respectively) were identically designed phase 3, double-masked, multicenter, randomized, sham injection-controlled clinical trials that evaluated intravitreal lampalizumab in GA. Participants: Eligible patients were 50 years of age or older with well..

View full abstract

University of Melbourne Researchers

Robyn Guymer Author

Grants

Funding Acknowledgements

Supported by F. Hoffmann-La Roche Ltd., Basel, Switzerland, which was involved in design and conduct of the studies; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. Funding was provided by F. Hoffmann-La Roche Ltd. for third-party writing assistance, which was provided by Anne Nunn, PhD, CMPP, of Envision Pharma Group.